Fate Therapeutics, Inc. (FATE) Wins $15M CIRM Grant for FT819 Phase 2 RECLAIM-LN
Fate Therapeutics received a $15.0M CIRM CLIN2 grant to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T in refractory SLE with lupus nephritis.Material DetailsContext by AI AnalystThis is mid-cycle support for an ongoing Phase 2 program, adding non-diluti…